ArticleiScience2025
Smurf2 enhances ubiquitin-mediated degradation of CASC3 and attenuates leukemia progression.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukemia is a prevalent cancer worldwide with a poor prognosis, underscoring the need to understand the molecular mechanisms driving its development and progression. Smurf2 has been implicated in the development of numerous cancer types; however, its specific role in leukemia remains elusive. In this study, we investigated the function of Smurf2 in leukemia progression. Our findings demonstrate that upregulation of Smurf2 reduces viability of leukemia cells and induces apoptosis. Moreover, we identified CASC3 as a substrate of Smurf2 in leukemia. Smurf2 interacts with CASC3 and regulates its ubiquitination and degradation. Notably, Smurf2-mediated degradation of CASC3 depends on its 137-283 domain and lysine residue K254. Strikingly, the downregulation of Smurf2 promotes cell viability through CASC3, while overexpression of Smurf2 retards tumor growth in mouse models. Collectively, our results suggest that the Smurf2/CASC3 axis may serve as a potential therapeutic target for the treatment of leukemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.